$10.6 Billion Acquisition Delivers Key Return! GSK's (GSK.US) New Lung Cancer Drug Nelkarmi Approved for Market, Targeting a Multi-Billion-Dollar Market
Zhito Finance APP has learned that GlaxoSmithKline's (GSK.US) lung cancer drug neladalkib has received marketing approval from the U.S. Food and Drug Administration (FDA), providing a new treatment option for patients whose disease continues to progress after prior ALK-targeted therapy, further validating the strategic value of the British pharmaceutical company's earlier acquisition of biotechnology company Nuvalent.
Latest

